RT Journal Article
SR Electronic
T1 The gut microbiome and rotavirus vaccine immunogenicity in rural Zimbabwean infants
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21254180
DO 10.1101/2021.03.24.21254180
A1 Robertson, Ruairi C.
A1 Church, James A.
A1 Edens, Thaddeus J.
A1 Mutasa, Kuda
A1 Geum, Hyun Min
A1 Baharmand, Iman
A1 Gill, Sandeep K.
A1 Ntozini, Robert
A1 Chasekwa, Bernard
A1 Carr, Lynnea
A1 Majo, Florence D.
A1 Kirkpatrick, Beth D.
A1 Lee, Benjamin
A1 Moulton, Lawrence H.
A1 Humphrey, Jean H.
A1 Prendergast, Andrew J.
A1 Manges, Amee R.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254180.abstract
AB Background Oral rotavirus vaccine (RVV) immunogenicity is considerably lower in low-versus high-income populations; however, the mechanisms underlying this remain unclear. Previous evidence suggests that the gut microbiota may contribute to differences in oral vaccine efficacy.Methods We performed whole metagenome shotgun sequencing on stool samples and measured anti-rotavirus immunoglobulin A in plasma samples from a subset of infants enrolled in a cluster randomized 2×2 factorial trial of improved water, sanitation and hygiene and infant feeding in rural Zimbabwe (SHINE trial: NCT01824940). We examined taxonomic and functional microbiome composition using random forest models, differential abundance testing and regression analyses to explored associations with RVV immunogenicity.Results Among 158 infants with stool samples and anti-rotavirus IgA titres, 34 were RVV seroconverters. The median age at stool collection was 43 days. The infant microbiome was dominated by Bifidobacterium longum. The gut microbiome differed significantly between early (≤42 days) and later samples (>42 days) however, we observed no meaningful differences in alpha diversity, beta diversity, species composition or functional metagenomic composition by RVV seroconversion status. Bacteroides thetaiotaomicron was the only species associated with anti-rotavirus IgA titre. Random forest models poorly classified seroconversion status by both composition and functional microbiome variables.Conclusions RVV immunogenicity is low in this rural Zimbabwean setting, however it is not explained by the composition or function of the early-life gut microbiome. Further research is warranted to examine the mechanisms of poor oral RVV efficacy in low-income countries.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01824940Funding StatementThis work was supported by the Wellcome Trust [203905/Z/16/Z to JAC, 206455/Z/17/Z to RCR and 093768/Z/10/Z and 108065/Z/15/Z to AJP]. The SHINE trial was funded by the Bill and Melinda Gates Foundation [OPP1021542 and OPP113707]; UK Department for International Development (UK Aid); Swiss Agency for Development and Cooperation and US National Institutes of Health [2R01HD060338-06]. The study funders approved the trial design, but were not involved in data collection, analysis, interpretation, or manuscript preparation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Research Council of Zimbabwe and the Institutional Review Board of the Johns Hopkins Bloomberg School of Public Health approved the study protocol.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIndividual level data will be uploaded by the trial team as individual participant data with an accompanying data dictionary at http://ClinEpiDB.org in mid 2021. This platform is charged with ensuring that epidemiological studies are fully anonymised by removing all personal identifiers and obfuscating all dates per participant through application of a random number algorithm to comply with the ethical conduct of human subjects research. Researchers must agree to the policies and comply with the mechanism of ClinEpiDB to access data housed on this platform. Prior to that time, the data are housed on the ClinEpiDB platform at the Zvitambo Institute for Maternal and Child Health Research and available upon request from Ms. Virginia Sauramba (vsauramba@zvitambo.co.zw).